Enveric Biosciences, Inc. (NASDAQ:ENVB – Get Free Report) saw a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 23,000 shares, a drop of 58.6% from the January 15th total of 55,600 shares. Approximately 0.9% of the shares of the company are short sold. Based on an average daily trading volume, of 95,600 shares, the short-interest ratio is currently 0.2 days.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Enveric Biosciences in a report on Tuesday, January 30th.
Enveric Biosciences Trading Up 5.0 %
Enveric Biosciences (NASDAQ:ENVB – Get Free Report) last released its quarterly earnings data on Monday, November 13th. The company reported ($1.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.63. On average, equities research analysts forecast that Enveric Biosciences will post -8.17 earnings per share for the current year.
Institutional Investors Weigh In On Enveric Biosciences
A number of large investors have recently modified their holdings of the stock. AdvisorShares Investments LLC boosted its stake in Enveric Biosciences by 46.2% during the third quarter. AdvisorShares Investments LLC now owns 146,833 shares of the company’s stock worth $339,000 after acquiring an additional 46,404 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Enveric Biosciences by 259.2% during the first quarter. Renaissance Technologies LLC now owns 1,990,600 shares of the company’s stock worth $657,000 after acquiring an additional 1,436,500 shares in the last quarter. Virtu Financial LLC boosted its stake in Enveric Biosciences by 96.3% during the first quarter. Virtu Financial LLC now owns 276,184 shares of the company’s stock worth $91,000 after acquiring an additional 135,474 shares in the last quarter. Millennium Management LLC bought a new stake in Enveric Biosciences during the second quarter worth about $49,000. Finally, Citadel Advisors LLC bought a new stake in Enveric Biosciences during the second quarter worth about $47,000. Institutional investors own 8.75% of the company’s stock.
Enveric Biosciences Company Profile
Enveric Biosciences, Inc develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs.
- Five stocks we like better than Enveric Biosciences
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 3 attractive stocks that insiders are buying
- Market Cap Calculator: How to Calculate Market Cap
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- How to Calculate Stock Profit
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.